Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
45.62
+3.02 (7.09%)
At close: Oct 30, 2025, 4:00 PM EDT
45.42
-0.20 (-0.44%)
After-hours: Oct 30, 2025, 7:59 PM EDT
BMY Revenue
Bristol-Myers Squibb Company had revenue of $12.22B in the quarter ending September 30, 2025, with 2.77% growth. This brings the company's revenue in the last twelve months to $48.03B, up 1.26% year-over-year. In the year 2024, Bristol-Myers Squibb Company had annual revenue of $48.30B with 7.32% growth.
Revenue (ttm)
$48.03B
Revenue Growth
+1.26%
P/S Ratio
1.93
Revenue / Employee
$1,408,622
Employees
34,100
Market Cap
92.86B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
| Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
| Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
| Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
| Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| Eli Lilly and Company | 59.42B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
BMY News
- 11 hours ago - Bristol-Myers Squibb Company (BMY) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 12 hours ago - Bristol Myers' New Treatments Drive Q3 Beat — And The Company's Raising Its Outlook - Benzinga
- 13 hours ago - Bristol-Myers Squibb Q3 Earnings Review: Despite Today's Gains, I See Trouble Ahead - Seeking Alpha
- 15 hours ago - 10 Ideal 'Safer' Dividend Buys From 38 Of 68 October Graham Value All-Stars (GVAS) - Seeking Alpha
- 19 hours ago - Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain. - Barrons
- 20 hours ago - Bristol Myers Squibb Profit Soars, Raises Revenue Guidance - WSJ
- 20 hours ago - Bristol Myers beats quarterly revenue estimates on strong Opdivo sales - Reuters
- 20 hours ago - Bristol Myers Squibb Reports Third Quarter Financial Results for 2025 - Business Wire